Humaan Albumine Csl Behring (Human Plasma Protein)

Humaan Albumine is indicated for clinical conditions where plasma volume and oncotic pressure need rapid restoration.

• Treatment of hypovolemia due to blood loss or fluid depletion.
• Management of circulatory shock, including septic or hemorrhagic shock.
• Support in severe burn injuries to maintain intravascular volume.
• Correction of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition.
• Adjunct during major surgery or transplantation to stabilize hemodynamics.

• Human albumin in Humaan Albumine raises plasma oncotic pressure by contributing to the colloid osmotic gradient. The infused albumin remains primarily within the vascular compartment, drawing water from the interstitial space into the bloodstream, thereby expanding intravascular volume. This effect supports circulatory stability and improves tissue perfusion without directly influencing cardiac contractility or vascular tone. The increase in oncotic pressure also helps to reduce edema formation by limiting fluid shift into the extracellular space.

Adverse reactions to Humaan Albumine are generally related to the infusion process or to the protein itself.

Common

• Mild fever or chills during or shortly after infusion.
• Transient hypotension or hypertension.
• Headache or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Localized erythema or swelling at the injection site.
• Mild flushing or sensation of warmth.

Serious

• Anaphylactic or severe allergic reactions, including urticaria and bronchospasm.
• Acute hemolysis or transfusion‑related acute lung injury (TRALI).
• Volume overload leading to pulmonary edema.
• Severe hypertension with risk of intracranial hemorrhage.
• Disseminated intravascular coagulation (rare).

Clinicians should evaluate patient history and clinical status before administering Humaan Albumine to minimize risks.

• Assess for known hypersensitivity to human albumin or any component of the solution.
• Evaluate fluid balance; avoid use in patients with uncontrolled heart failure or severe renal impairment.
• Monitor vital signs and central venous pressure during infusion, especially in critically ill patients.
• Use caution in patients with active bleeding disorders or coagulopathy.
• Adjust infusion rate in individuals at risk for volume overload or pulmonary edema.
• Consider pregnancy status; limited safety data are available.

Humaan Albumine may interact with other therapies that affect fluid balance, coagulation, or immune response.

Avoid

• Concomitant administration of other volume expanders or colloids without careful monitoring.
• Simultaneous infusion of blood products that are not compatible, which can increase risk of hemolysis.

Use with caution

• Diuretics, as they may counteract the intended volume expansion.
• Vasopressors, because rapid volume changes can alter hemodynamic response.
• Anticoagulants, since changes in plasma protein levels may affect coagulation monitoring.
• Immunosuppressive agents, due to potential for altered immune reactions.